Document is current
Any future updates will be listed below
-
Authors
Ross, Carolyn https://orcid.org/0000-0002-2891-3245
Ducharme-Bénard, Stéphanie https://orcid.org/0000-0003-1555-3815
Hussein, Samer https://orcid.org/0000-0002-2136-7448
Meunier, Rosalie-Sélène https://orcid.org/0009-0007-1383-6957
Pagnoux, Christian https://orcid.org/0000-0001-6287-9549
Makhzoum, Jean-Paul https://orcid.org/0000-0003-4523-8525
- License Information
-
More Information
Article History
Received: 14 June 2024
Revised: 28 July 2024
Accepted: 1 August 2024
First Online: 7 August 2024
Compliance with ethical standards
:
: The study was conducted in accordance with the Declaration of Helsinki and was approved by our institution’s research ethics board (protocol number 20201890, Sacre-Coeur Hospital, Montreal, Quebec, Canada). All patients consented to be enrolled in this study and provided informed signed consent.
: Dr. Ross has received consultation fees from Otsuka® outside the submitted work. Dr. Ducharme-Bénard has received presentation and focus group fees from Novartis® outside the submitted work. Dr. Hussein has received presentation fees from Janssen® and is an investigator in clinical trials funded by Astra-Zeneca outside the submitted work. Dr. Pagnoux has received consultation or presentation fees from Roche®, Otsuka®, GlaxoSmithKline®, Astra-Zeneca®, Sanofi ®, BMS®, and ChemoCentryx® and has received research funds from CanVasc, the Vasculitis Clinical Research Consortium (VCRC), GSK®, Astra-Zeneca®, and Otsuka® outside the submitted work. Dr. Makhzoum has received consultation or presentation fees from Roche®, Otsuka®, GlaxoSmithKline®, Astra-Zeneca®, and Sanofi ® and is an investigator in clinical trials funded by Health Canada, the Vasculitis Clinical Research Consortium (VCRC), Janssen®, and Novartis® outside the submitted work. All other authors had no conflicts of interests to declare.
